Sign In
Last checked at 
2 Nov 2015 15:38
2 November 2015
IXICO plc
Total Voting Rights
In accordance with the requirements of the FCA's Disclosure and Transparency Rule 5.6.1, IXICO plc (Ticker: IXI) ('IXICO' or the 'Company') confirms that the Company's issued share capital consists of 15,215,664 ordinary shares of 50p each in issue, each with equal voting rights. No shares are held in treasury.
The above figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interest, or a change to their interest, in the Company under the FCA's Disclosure and Transparency Rules.
Enquiries:
IXICO plc | +44 20 3763 7499 |
Derek Hill, CEO |
|
Susan Lowther, CFO |
|
Charles Spicer, VP Corporate Development |
|
|
|
Peel Hunt LLP (Nominated Adviser and Broker) | +44 20 7418 8900 |
James Steel |
|
Oliver Jackson |
|
|
|
Daniel Stewart & Company (Joint Broker) | +44 207 776 6550 |
Martin Lampshire |
|
David Coffman |
|
|
|
FTI Consulting Limited (Investor Relations) | +44 20 3727 1000 |
Simon Conway |
|
Mo Noonan |
|
Matthew Moss |
|
Notes to Editors
About IXICO
IXICO, the brain health company, uses its innovative and proprietary digital platform technologies to help those involved in researching and treating serious diseases to make rapid, informed decisions targeted at improving patient outcomes. IXICO has significant experience working with global pharmaceutical and biotechnology companies supporting clinical studies in the field of neuro-degenerative disorders including dementia, Alzheimer's disease, Huntington's disease and Multiple Sclerosis.
More information is available on www.ixico.com
Follow the stocks
